nelfinavir has been researched along with Disease Models, Animal in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Connis, N; Dennis, PA; Gills, JJ; Hann, CL; Kawabata, S | 1 |
| Cruz, JP; Machado, M; Mendes, AM; Prudêncio, M; Sanches-Vaz, M | 1 |
| Fuselier, T; Gongora, R; Lasky, JA; MacKinnon, SS; Molinski, SV; Mondal, D; Sanchez, CG; Sosulski, M | 1 |
| Carrillo, E; Mejías, F; Moreno, J; Sánchez, C; Valdivieso, E | 1 |
| Al-Assar, O; Bittner, MI; Brunner, TB; Lunardi, S; McKenna, WG; Stratford, MR | 1 |
| De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Panes, R; Ryazanov, AG; Zaffalon, L | 1 |
| Bashan, N; Ben-Romano, R; Hou, JC; Kachko, I; Maissel, A; Mazor, L; Pessin, JE; Rudich, A; Watson, RT | 1 |
| Algeciras-Schimnich, A; Badley, AD; Bren, GD; Chari, ST; Dawra, RK; Navina, S; Rizza, SA; Saluja, AK; Schnepple, D; Singh, VP; Vege, SS | 1 |
| Andrews, S; Carlson, GA; Hanamsagar, R; Huang, Y; Ikezu, T; Kiyota, T; Lan, X; Peng, H; Swindells, S; Zheng, JC | 1 |
| Badley, AD; Bennett, SA; Bren, GD; Brenner, C; Deniaud, A; Dong, L; Douen, A; Hardin, H; Hou, ST; Jiang, SX; Kroemer, G; Kroemer, RT; Lallier, J; Lebras, M; Lynch, DH; Moffat, TC; Morin, MY; Phenix, BN; Sim, VL; Tarze, A; van Heeswijk, RP; Weaver, JG; Wettstein, P; Zurakowski, B | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
11 other study(ies) available for nelfinavir and Disease Models, Animal
| Article | Year |
|---|---|
Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Repositioning; Female; Humans; Lung Neoplasms; Mice; Nelfinavir; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2021 |
Inhibition of
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cell Line; Cyclopropanes; Disease Models, Animal; Hepatocytes; Humans; Malaria; Male; Mice, Inbred C57BL; Nelfinavir; Nitriles; Plasmodium berghei; Pyridazines; Pyrimidines | 2017 |
The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.
Topics: Animals; Anti-Retroviral Agents; Cell Culture Techniques; Cell Differentiation; Computer Simulation; Disease Models, Animal; Fibroblasts; Humans; Lung; Male; Mice; Mice, Inbred C57BL; Nelfinavir; Pulmonary Fibrosis; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta1 | 2018 |
Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Survival; Disease Models, Animal; Drug Synergism; Humans; Leishmania infantum; Leishmaniasis, Visceral; Liver; Male; Mice, Inbred BALB C; Nelfinavir; Parasite Load; Phosphorylcholine; Spleen; Treatment Outcome | 2018 |
The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; HIV Protease Inhibitors; Mice; Mice, Nude; Nelfinavir; Pancreatic Neoplasms; Pancreatic Stellate Cells; Radiation-Sensitizing Agents | 2016 |
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Elongation Factor 2 Kinase; Female; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Nelfinavir; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; TOR Serine-Threonine Kinases; Tumor Burden | 2016 |
Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Membrane; Disease Models, Animal; Glucose; Glucose Transporter Type 4; Green Fluorescent Proteins; HIV Protease Inhibitors; Insulin; Insulin Resistance; Mice; Nelfinavir; Phosphatidylinositol Phosphates; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Insulin; Signal Transduction | 2009 |
Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.
Topics: Amylases; Animals; Apoptosis; Caspase 3; Ceruletide; Cytochromes c; Disease Models, Animal; Drug Therapy, Combination; HIV Protease Inhibitors; Inflammation Mediators; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria; Necrosis; Nelfinavir; Pancreas; Pancreatitis; Ritonavir; Trypsin | 2009 |
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atazanavir Sulfate; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Lopinavir; Macrophages; Mice; Mice, SCID; Mice, Transgenic; Nelfinavir; Neurons; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2012 |
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.
Topics: Animals; Antibodies; Apoptosis; Disease Models, Animal; Female; Hepatitis; HIV Protease Inhibitors; Humans; Jurkat Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitochondrial ADP, ATP Translocases; Models, Molecular; Nelfinavir; Ritonavir; Shock, Septic; Signal Transduction; Stroke | 2005 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |